166MO A phase III trial to compare the efficacy, safety, pharmacokinetics and immunogenicity of HD201 to trastuzumab in HER2+ early breast cancer patients (TROIKA)
| Autor: | Xavier, P., Hii, C.S.J., Mclendon, K., Feyaerts, P., Felicia, A., J. litha, Demarchi, M.F., Coliat, P., Deforce, F., Derde, M.P., Kim, M.J., Park, L.S. |
|---|---|
| Zdroj: | In Annals of Oncology September 2020 31 Supplement 4:S307-S307 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|